Skip to content

G&A at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$62.59M+302%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$101.25M+189%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s G&A?
Nuvalent, Inc. (NUVL) reported G&A of $35.8M in Q1 2026.
How has Nuvalent, Inc.'s G&A changed year-over-year?
Nuvalent, Inc.'s G&A increased by 75.5% year-over-year, from $20.39M to $35.8M.
What is the long-term trend for Nuvalent, Inc.'s G&A?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s G&A has grown at a 79.9% compound annual growth rate (CAGR), from $10.26M to $107.34M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.